Menu
Recruiting NCT06965426

Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study

No phase Interventional Macular Degenerative Disease

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation.
Who it may be relevant to
Registry conditions: Macular Degenerative Disease. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

To compare skin carotenoid scores over 12 weeks of individuals randomized to placebo or MacuHealth and comparing that to a 12 week crossover evaluation.

Interventions

  • Other Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation
    Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation

Primary outcome measures

  • Carotenoid concentration [Time frame: 6 months]

Eligibility criteria

Inclusion criteria

  • Adult patients 18-50 years old of any sex and any race.
  • Willing to comply with the protocol instructions.
  • Has read (or has had read to), understood, and signed an Informed Consent.

Exclusion criteria

  • Current Smoker
  • Pregnant, plan to become pregnant or breastfeeding
  • History of any non-controlled disease states including diabetes, cancer, heart diseases ETC (we need to confirm this with previous protocols) BMI greater than 30
  • Currently taking MacuHealth or similar supplements or previous use

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Randomized
Model
Crossover
Masking
Double blind
Primary purpose
Prevention

Study locations

United States · 1 center
  • Vision Source — Kansas City

Identifiers

NCT: NCT06965426 · VSE001

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗